NASDAQ: CRON · Life Sciences · 3 alerts · CIK 1656472
Share price
$3.27Close, Nov 16
Market cap
$1.2B
Shares outstanding
366.47MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cronos Group Inc. filings on SEC EDGAR ↗
Cronos Group reported a significant increase in net revenue to $63.5 million for Q3 2026, up from $36.3 million in the prior year period, driven by growth in cannabis sales. The company achieved an operating income of $9.0 million for the quarter, a substantial improvement from the operating loss of $0.5 million in Q3 2025, while maintaining a strong cash and short-term investment position of approximately $741 million.
Cronos Group reported record Q3 2026 financial results, with net revenue increasing 75% year-over-year to $63.5 million. The company achieved record performance in Canada, Israel, and Germany, while maintaining a strong balance sheet and continuing its share repurchase program.
Term
Q3 2026
“Cronos organically achieved records across net revenue, gross profit, and Adjusted EBITDA for the second consecutive quarter, while at the same time reducing shares outstanding.”
Mike Gorenstein, Chairman, President and CEO
“Our strategic focus on the development and production of market-leading borderless products continues to pay off, reflected in another record quarter of results.”
Cronos Group completed the acquisition of CanAdelaar B.V., a licensed cannabis grower in the Dutch Controlled Cannabis Supply Chain Experiment, for a base purchase price of €57.5 million plus earnouts. The deal establishes Cronos' European platform in the Netherlands' adult-use cannabis pilot program, with the buyer deducting €12.5 million from the initial price to cover a potential environmental penalty.